Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
BADOUX, Xavier C, KEATING, Michael J, SIJIN WEN, WIERDA, William G, O'BRIEN, Susan M, PADERL, Stefan, SARGENT, Rachel, BURGER, Jan A, FERRAJOLI, Alessandra
Published in Journal of clinical oncology (10.02.2013)
Published in Journal of clinical oncology (10.02.2013)
Get full text
Journal Article
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
Wierda, William G, Allan, John N, Siddiqi, Tanya, Kipps, Thomas J, Opat, Stephen, Tedeschi, Alessandra, Badoux, Xavier C, Kuss, Bryone J, Jackson, Sharon, Moreno, Carol, Jacobs, Ryan, Pagel, John M, Flinn, Ian, Pak, Yvonne, Zhou, Cathy, Szafer-Glusman, Edith, Ninomoto, Joi, Dean, James P, James, Danelle F, Ghia, Paolo, Tam, Constantine S
Published in Journal of clinical oncology (01.12.2021)
Published in Journal of clinical oncology (01.12.2021)
Get full text
Journal Article
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL
Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Published in Blood (17.03.2011)
Published in Blood (17.03.2011)
Get full text
Journal Article
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax
Jain, Nitin, Croner, Lisa J, Allan, John N, Siddiqi, Tanya, Tedeschi, Alessandra, Badoux, Xavier C, Eckert, Karl, Cheung, Leo W K, Mukherjee, Anwesha, Dean, James P, Szafer-Glusman, Edith, Seymour, John F
Published in Clinical cancer research (01.02.2024)
Published in Clinical cancer research (01.02.2024)
Get full text
Journal Article
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
Allan, John N, Flinn, Ian W, Siddiqi, Tanya, Ghia, Paolo, Tam, Constantine S, Kipps, Thomas J, Barr, Paul M, Elinder Camburn, Anna, Tedeschi, Alessandra, Badoux, Xavier C, Jacobs, Ryan, Kuss, Bryone J, Trentin, Livio, Zhou, Cathy, Szoke, Anita, Abbazio, Christopher, Wierda, William G
Published in Clinical cancer research (14.07.2023)
Published in Clinical cancer research (14.07.2023)
Get full text
Journal Article
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
Badoux, Xavier C., Keating, Michael J., Wen, Sijin, Lee, Bang-Ning, Sivina, Mariela, Reuben, James, Wierda, William G., O'Brien, Susan M., Faderl, Stefan, Kornblau, Steven M., Burger, Jan A., Ferrajoli, Alessandra
Published in Blood (29.09.2011)
Published in Blood (29.09.2011)
Get full text
Journal Article
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
Strati, Paolo, Keating, Michael J., Wierda, William G., Badoux, Xavier C., Calin, Steliana, Reuben, James M., O'Brien, Susan, Kornblau, Steven M., Kantarjian, Hagop M., Gao, Hui, Ferrajoli, Alessandra
Published in Blood (01.08.2013)
Published in Blood (01.08.2013)
Get full text
Journal Article
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Published in Blood (25.08.2011)
Published in Blood (25.08.2011)
Get full text
Journal Article
Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia
Alattar, Mona Lisa, Ciccone, Maria, Gaballa, Mahmoud R., Vitale, Candida, Badoux, Xavier C., Manoukian, George, Keating, Michael J., Kroll, Michael H., Ferrajoli, Alessandra
Published in Leukemia & lymphoma (02.12.2015)
Published in Leukemia & lymphoma (02.12.2015)
Get full text
Journal Article
What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?
Badoux, Xavier C., Keating, Michael J., Wierda, William G.
Published in Current hematologic malignancy reports (01.03.2011)
Published in Current hematologic malignancy reports (01.03.2011)
Get full text
Journal Article
Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study
Wierda, William G., Jacobs, Ryan, Barr, Paul M., Allan, John N., Siddiqi, Tanya, Tedeschi, Alessandra, Kipps, Thomas J., O'Brien, Susan Mary, Badoux, Xavier C., Visentin, Andrea, Lasica, Masa, Carney, Dennis, Elinder Camburn, Anna, De La Serna Torroba, Javier, Szafer-Glusman, Edith, Zhou, Cathy, Szoke, Anita, Dean, James P., Ghia, Paolo, Tam, Constantine S.
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Kuss, Bryone J., Badoux, Xavier C., Barrientos, Jacqueline C., Tedeschi, Alessandra, Opat, Stephen, Flinn, Ian W., Gonzalez Barca, Eva, Jacobs, Ryan, Szafer-Glusman, Edith, Zhou, Cathy, Szoke, Anita, Wierda, William G., Ghia, Paolo, Tam, Constantine S.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study
Ghia, Paolo, Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Kuss, Bryone J., Opat, Stephen, Flinn, Ian W., Badoux, Xavier C., Tedeschi, Alessandra, Gonzalez-Barca, Eva, Pagel, John M., Jacobs, Ryan, Barrientos, Jacqueline, Szafer-Glusman, Edith, Zhou, Cathy, Ninomoto, Joi, Dean, James P., Tam, Constantine S., Wierda, William G.
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
Tam, Constantine S., Siddiqi, Tanya, Allan, John N., Kipps, Thomas J., Flinn, Ian W., Kuss, Bryone J., Opat, Stephen, Barr, Paul M., Tedeschi, Alessandra, Jacobs, Ryan, Badoux, Xavier C., Ghia, Paolo, Sukbuntherng, Juthamas, Salem, Ahmed Hamed, Russell, Kristin, Eckert, Karl, Zhou, Cathy, Ninomoto, Joi, James, Danelle F., Wierda, William G.
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
CLL-057 Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
Wierda, William G., Jacobs, Ryan, Barr, Paul M., Allan, John N., Siddiqi, Tanya, Tedeschi, Alessandra, Kipps, Thomas J., O'Brien, Susan M., Badoux, Xavier C., Visentin, Andrea, Lasica, Masa, Carney, Dennis, Elinder Camburn, Anna, De la Serna, Javier, Szafer-Glusman, Edith, Zhou, Cathy, Szoke, Anita, Dean, James P., Ghia, Paolo, Tam, Constantine S.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib (Ibr) + Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
Wierda, William G., Jacobs, Ryan, Barr, Paul M., Allan, John N., Siddiqi, Tanya, Tedeschi, Alessandra, Kipps, Thomas J., O'Brien, Susan M., Badoux, Xavier C., Visentin, Andrea, Lasica, Masa, Carney, Dennis, Elinder Camburn, Anna, De la Serna, Javier, Szafer-Glusman, Edith, Zhou, Cathy, Szoke, Anita, Dean, James P., Ghia, Paolo, Tam, Constantine S.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study
Wierda, William G., Tam, Constantine S., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Opat, Stephen, Tedeschi, Alessandra, Badoux, Xavier C., Kuss, Bryone J., Jackson, Sharon, Moreno, Carol, Jacobs, Ryan, Pagel, John M., Flinn, Ian W., Zhou, Cathy, Szafer-Glusman, Edith, Ninomoto, Joi, Dean, James P., James, Danelle F., Ghia, Paolo
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Increasing Cross-Referral and Recruitment to Clinical Trials: A New Approach
Ristuccia, Roslyn, Badoux, Xavier C, Gibson, Melinda, Huseincehajic, Admir, Trotman, Judith
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
Molecular and Genetic Characterization of Fit, Elderly Patients Receiving Oral Fludarabine, Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As Initial Treatment of Chronic Lymphocytic Leukemia (CLL)
Badoux, Xavier C, Best, Giles, Gabrielli, Sara, Hayes, Melanie, Zhu, Ying, Mulligan, Stephen, Kuss, Bryone J
Published in Blood (06.12.2014)
Published in Blood (06.12.2014)
Get full text
Journal Article
High, durable minimal residual disease negativity (MRD–) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study
Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W, Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny, Mobasher, Mehrdad
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article